• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AIX and BGM Group Forge Strategic Deal, Leading Healthcare, Pharma, and Insurance Industry Expansion with AI

    11/29/24 9:00:00 AM ET
    $AIFU
    $BGM
    Specialty Insurers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIFU alert in real time by email

    GUANGZHOU, China, Nov. 29, 2024 (GLOBE NEWSWIRE) -- AIX Inc. (NASDAQ:AIFU) (the "Company" or "AIX"), a leading independent technology-driven financial services provider in China, today announced that it has entered into a strategic transaction agreement (the "Agreement") with BGM Group Ltd. (NASDAQ:BGM) ("BGM"), a leading global provider of premium pharmaceutical products and services. Pursuant to the Agreement, AIX agreed to transfer the equity interests of its intelligent platform consisting of RONS Intelligent Technology (Beijing) Co., Ltd. ("RONS Technology") and Shenzhen Xinbao Investment Management Co., Ltd. ("Xinbao Investment"), valued at approximately US$140.0 million, to BGM in exchange for 69,995,661 of BGM's Class A ordinary shares, at a consideration valuation of US$2.00 per share.

    The transaction is expected to close by the end of 2024, subject to certain closing conditions. Upon completion of the transaction, AIX will hold approximately 72.0% of BGM's equity interests and approximately 3.4% of its voting power while BGM will gain full control of RONS Technology and Xinbao Investment.

    The Company anticipates that RONS Technology and Xinbao Investment will both gain broader development opportunities through this transaction. BGM's extensive resources in the healthcare sector will create more application scenarios for both parties' products and services, further unlocking their growth potential. AIX, through its shareholding in BGM, will indirectly participate in the value creation of RONS Technology and Xinbao Investment, ensuring that its shareholders can continue to benefit from their future value growth.

    Additionally, this transaction will accelerate AIX's strategic expansion into the pharmaceutical and healthcare sector. This will enable the Company to fully capitalize on the opportunities brought by the aging population and the silver economy in China, injecting new momentum into the company's future growth.

    Mr. Yinan Hu, Chief Executive Officer of AIX, commented: "AI-driven innovation is the future of the insurance industry. Our platform has already shown tremendous potential within the insurance sector, but achieving broader growth requires a more open perspective and stronger ecosystem support. We believe this partnership with BGM will allow our intelligent platform to reach a broader user base and unleashes the potential of AI technologies beyond insurance.

    "This collaboration represents an important milestone in our strategic transformation. BGM, as a leading global player in the pharmaceutical industry, brings deep expertise, an international perspective, and a solid industry position, all of which will help fuel the development of our intelligent platform in the pharmaceutical and healthcare sectors. With this partnership, we will be able to expand our intelligent capabilities from insurance to the pharmaceutical and healthcare industries to seize opportunities in the silver economy, and foster higher-quality development.

    "We will continue to be a key user of the intelligent platform and actively invest resources to unlock its technological potential. We firmly believe that this partnership will unlock immense opportunities for both AIX and our intelligent platform while delivering greater long-term value to our clients, partners and shareholders."

    Mr. Chen Xin, Chief Executive Officer of BGM, stated, "We are deeply impressed by AIX's achievements in digitalization and intelligent transformation. Their expertise and technological advancements offer valuable insights for advancing our intelligent transformation in the healthcare and pharmaceutical sectors. We believe that this partnership will not only strengthen our technological competitiveness but also accelerate our strategic positioning, enabling us to provide more efficient and intelligent solutions to the global market. I look forward to a mutually beneficial collaboration that will shape the future of both parties."

    BGM operates through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. and its affiliates. Since its inception in 1969, BGM has evolved into a leading provider of premium products and services within the global pharmaceutical industry, skillfully harnessing over 50 years of cutting-edge biotechnological production expertise in bio-fermentation, bio-extraction, and pharmaceutical formulation. BGM has established a strong position in the international pharmaceutical industry through extensive pharmaceutical experience, innovative technique, and expansion into global markets.

    Founded in 2009, RONS Technology, a wholly-owned subsidiary of AIX, specializes in developing digital and intelligent technologies for the financial and insurance industries. RONS Technology boasts extensive experience in insurtech, having introduced disruptive innovations through its RONS Open Platform and flagship product Du Xiaobao. RONS Technology has steadily built a strong presence within the insurtech landscape, offering substantial growth potential and development opportunities.

    Established in 2004, Xinbao Investment, an affiliate under AIX's control, has developed a professional integrated online and offline insurance trading and service platform known as "Baowang". Baowang provides comprehensive risk protection solutions for individuals, families, and small to medium-sized enterprises through the integration of technology, products, and services. The platform currently offers over 300 flagship products from more than 30 insurance companies, addressing various protection needs such as critical illness, term life, accident, health, travel, and corporate insurance.

    About AIX Inc.

    AIX, established in 1998, is a leading intelligent technology-driven independent financial services provider in China. It provides 400 million middle-class families with insurance protection, wealth management, and value-added services and provides independent financial advisors and various insurance/financial sales organizations with technical support and comprehensive solutions. Through AI-driven insights and cutting-edge digital tools, AIX has successfully established itself as a leader in intelligent transformation within the financial services industry.

    Forward-looking Statements

    This press release contains statements of a forward-looking nature. These statements, including the statements relating to the Company's future financial and operating results, are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as "will", "expects", "believes", "anticipates", "intends", "estimates" and similar statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about AIX Inc. and the industry. Potential risks and uncertainties include, but are not limited to, those relating to its ability to attract and retain productive agents, especially entrepreneurial agents, its ability to maintain existing and develop new business relationships with insurance companies, its ability to execute its growth strategy, its ability to adapt to the evolving regulatory environment in the Chinese insurance industry, its ability to compete effectively against its competitors, quarterly variations in its operating results caused by factors beyond its control including macroeconomic conditions in China. Except as otherwise indicated, all information provided in this press release speaks as of the date hereof, and AIX Inc. undertakes no obligation to update any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although AIX Inc. believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. Further information regarding risks and uncertainties faced by AIX Inc. is included in AIX Inc.'s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.

    For more information, please contact:

    AIX Inc. 

    Investor Relations

    Tel: +86 (20) 8388-3191

    Email: [email protected]



    Primary Logo

    Get the next $AIFU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What is the nature of the agreement between AIX Inc. and BGM Group Ltd.?

      AIX Inc. is transferring its equity interests in RONS Technology and Xinbao Investment to BGM in exchange for approximately 70 million shares of BGM's Class A ordinary shares, valued at $2.00 per share.

    • When is the expected closing date for the transaction between AIX and BGM?

      The transaction is expected to close by the end of 2024, subject to certain closing conditions.

    • What will be the ownership stakes of AIX and BGM after the transaction?

      Upon completion of the transaction, AIX will hold about 72.0% of BGM's equity interests and 3.4% of its voting power, granting BGM full control over RONS Technology and Xinbao Investment.

    • What benefits does AIX foresee from the transaction with BGM?

      AIX anticipates that the transaction will unlock broader development opportunities for both RONS Technology and Xinbao Investment by leveraging BGM's resources in the healthcare sector, enhancing growth potential.

    • Why is AIX pursuing this strategic transaction with BGM?

      AIX's strategic expansion into the pharmaceutical and healthcare sectors aims to capitalize on the opportunities presented by the aging population and the silver economy in China, thereby driving future growth.

    Recent Analyst Ratings for
    $AIFU
    $BGM

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $AIFU
    $BGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BGM Group Announces Strategic Acquisition of HM Management to Expand AI Application Ecosystem

      CHENGDU, China, May 2, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) (the "Company" or "BGM") , a leading AI technology company, today announced it has entered into a definitive agreement (the "Agreement") to acquire HM Management Company Limited ("HM Management"), a prominent AI agent production platform, in an all-stock transaction valued at approximately RMB300 million (US$41.7 million). Under the Agreement, BGM will issue 16,663,427 Class A ordinary shares at $2.50 per share to acquire 100% ownership of HM Management and its two wholly-owned subsidiaries: Beijing Shuda Technology Company Limited. ("Shuda Technology") and New Media Star Technology (Shenzhen) Co., Ltd ( "New Media Star

      5/2/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Completes Acquisition of YX to Advance AI-Powered Intelligent Platform

      CHENGDU, China, April 28, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) (the "Company" or BGM)  today announced the completion of its acquisition of YX Management Company Ltd. ("YX"), an leading intelligent mobility technology platform, on April 25, 2025. As previously disclosed, BGM acquired 100% of YX by issuing 47.5 million Class A ordinary shares to YX's existing shareholders, representing a valuation of US$95.0 million. Upon completion of the acquisition, YX's shareholders collectively own approximately 32.6% of BGM's equity interests and approximately 2.2% of the total voting power. This acquisition represents a significant step in BGM's AI-driven transformation, enhancing its capa

      4/28/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AIFU Files Annual Report on Form 20-F on April 25, 2025

      GUANGZHOU, China, April 25, 2025 (GLOBE NEWSWIRE) -- AIFU Inc. (NASDAQ:AIFU) (the "Company" or "AIFU"), a leading AI-driven independent financial services platform in China, today announced that it has filed its 2024 annual report on Form 20-F (the "2024 20-F"), which contains its audited financial statements for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the "SEC") on April 25, 2025. The 2024 20-F can be accessed on the SEC's website at http://www.sec.gov as well as on the Investor Relations page of the Company's website at http://ir.aifugroup.com/financial-information/sec-filings. Hard copies of the annual report are available, free of char

      4/25/25 5:00:47 PM ET
      $AIFU
      Specialty Insurers
      Finance

    $AIFU
    $BGM
    Leadership Updates

    Live Leadership Updates

    See more
    • BGM Group Announces Board Reshuffle: New Leadership Embarks on a Transformative Journey Amid Tech Revolution

      CHENGDU, China, Feb. 28, 2025 /PRNewswire/ -- BGM Group Ltd (NASDAQ:BGM) (the "Company" or "BGM") today announced changes to its board of directors, marking the Company's entry into a new phase of technological transformation and sustainable growth. Mr. Zhanchang Xin has tendered his resignation and will step down from his role as Chairman of the Company, effective March 1, 2025. He will be succeeded by Mr. Chen Xin, the current Chief Executive Officer of the Company, who will assume the position of Chairman. As the founder of the Company, Mr. Zhanchang Xin has, over the past six decades, has played a pivotal role in leading the Company through numerous challenges and milestones, including

      2/28/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Group Establishes "Duxiaobao Management Committee" to Accelerate AI Strategy and Drive Intelligent Transformation in the Insurance Industry

      CHENGDU, China, Feb. 19, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) announced the establishment of the "Duxiaobao Management Committee," which will be fully responsible for the management and decision-making of the "Duxiaobao" ecosystem. This move signifies BGM Group's strategic entry into the field of artificial intelligence, aiming to accelerate the transformation of the insurance industry into the smart era through AI technology. The Duxiaobao Management Committee consists of industry leaders such as Xin Chen, Li Yuqing, Ge Peng, Zhao Qi, Ren Yong, Li Jun, Zhou Xin, and Wang Hui. The committee has appointed Li Yuqing as the CEO of Duxiaobao, with Li Jun, Ren Yong, Zhou Xin, and Tan

      2/19/25 7:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AIX Announces Changes to the Board of Directors and Management Team

      GUANGZHOU, China, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The board of directors (the "Board") of AIX Inc. (NASDAQ:AIFU) (the "Company" or "AIX"), a leading independent technology-driven financial services provider in China, today announced that Mr. Ning Li has been appointed as Co-Chief Executive Officer and Executive Director of the Board, effective immediately. Mr. Ning Li served as Executive Director from 2017 to 2022 and Chief Financial Officer from 2010 to 2022 at CNFinance Holdings Ltd. Prior to that, he served as a Financial Director at AIX Inc. from 2006 to 2009. He served as Financial Controller at China Textile Import & Export Group and a Financial Director in one of its foreign repr

      11/22/24 6:37:06 AM ET
      $AIFU
      Specialty Insurers
      Finance

    $AIFU
    $BGM
    Financials

    Live finance-specific insights

    See more
    • BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

      CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 38,165,290 Class A ordinary shares at a price of $2 per share, for a total transaction valuation of RMB550 million. The transaction is expected to be completed in the second quarter of 2025. Wonder Dragon possesses over 3,000 metric tons of premium Qingzhuan dark tea inventory, comprising 1,670 metric tons of raw materials and 1,350 metric tons of finished products. These premium tea products, known f

      4/21/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Acquires YX to Strengthen AI Strategy for Its Intelligent Platform

      CHENGDU, China, March 19, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM) (NASDAQ:BGM) today announced that it has signed a definitive agreement with the existing shareholders of YX Management Company Ltd. ("YX"), a smart mobility technology company. Under the agreement, BGM will acquire 100% of the equity interests of YX by issuing 47.5 million class A ordinary shares to its existing shareholders, valuing YX at US$95.0 million. This acquisition is based on the exceptional expertise and experience of the YX team in scalable operations, digital infrastructure development, and technology commercialization. The integration of this team will accelerate the AI-driven strategic upgrade

      3/19/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIFU
    $BGM
    SEC Filings

    See more
    • SEC Form 6-K filed by AIFU Inc.

      6-K - AIFU Inc. (0001413855) (Filer)

      5/16/25 7:00:30 AM ET
      $AIFU
      Specialty Insurers
      Finance
    • Amendment: SEC Form 20-F/A filed by BGM Group Ltd.

      20-F/A - BGM Group Ltd. (0001779578) (Filer)

      5/8/25 8:04:36 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BGM Group Ltd.

      6-K - BGM Group Ltd. (0001779578) (Filer)

      5/6/25 9:06:17 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIFU
    $BGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by BGM Group Ltd.

      SC 13D - BGM Group Ltd. (0001779578) (Subject)

      12/3/24 6:03:06 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BGM Group Ltd.

      SC 13D/A - BGM Group Ltd. (0001779578) (Subject)

      11/29/24 9:00:27 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Qilian International Holding Group Ltd.

      SC 13D - Qilian International Holding Group Ltd (0001779578) (Subject)

      10/16/24 4:19:46 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care